文献库搜索 | GeneLibs

Kasi(A),Al-Rajabi(RMT),Baranda(JC),Saeed(A... Oncologist 2026-07-08

...BRCA1/2 germline mutation-positive patient group (n = 14) reported a 6-month PFS rate of 50% and a median overall surviv...

Beasley(HK),Shah(T),Tinker(RJ),Weidner(A),... Cancer 2026-06-15

...BRCA1 carriers (23.6% vs. 75.5%; p < .001), and family history of breast cancer was significantly more frequent among BR...

Arab(W),Kassis(NE),Khoury(C),Mansour(H),Ch... Gynecol Oncol Rep 2026-06-00

...BRCA1 mutation was identified on tumor sequencing and was subsequently confirmed as a germline pathogenic variant. Compl...

Ma(F),Xu(B),China Anti‐Cancer Association ... Cancer Innov 2026-06-00

...BRCA1/2 mutations. By selectively inhibiting DNA repair in tumor cells, these agents induce a "synthetic lethality" effe...

Qurat Ul Ain(H),Imam(W),Junaid Tahir(M),Ab... Ann Med Surg (Lond) 2026-06-00

...BRCA1 and BRCA2 genes. These defective genes pass from generation to generation. Germline testing helps in screening pat...

Wang(C),Zhu(M),Bao(L),Toffessi Tcheuyap(V)... J Exp Clin Cancer Res 2026-06-09

...BRCA1/2 mutations. Clear cell renal cell carcinoma (ccRCC) carrying wild type (WT) BRCA1/2 is resistant to PARP inhibito...

Acker(L),Chen(H) Cells Dev 2026-06-09

...BRCA1, yet its function in early development is poorly characterized. In this review, we investigate BRCA1 conservation ...

Kiljańczyk(M),Daneberga(Z),Tooming(M),Urba... Eur J Hum Genet 2026-06-09

...BRCA1/2 founders). All 21 countries offer NGS panel tests for hereditary breast and ovarian cancer, and ≥19 countries do...

Cheng(HH),Maxwell(KN),Salari(K),Cooperberg... BJU Int 2026-06-09

...BRCA1, MSH2, MSH6, CHEK2 and TP53. However, the optimal early detection strategy for gPV carriers, including use of age-...

Nguyen(AA),Cohen(EA),Ehsan(S),Mankowski(WC... Cancer Epidemiol Biomarkers... 2026-06-10

...BRCA1/2 pathogenic variants (PV) is unclear. We investigated the longitudinal association of quantitative BPE measures w...